Neuren Pharmaceuticals (ASX: NEU) has announced promising top-line results from its Phase 2 clinical trial of NNZ-2591, aimed at treating children with Pitt Hopkins syndrome (PTHS), a neurodevelopmental disorder with no approved treatments to date. The trial demonstrated statistically significant improvements across all four specifically designed efficacy measures, much to the optimism of clinicians and […]
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases, today disclosed promising topline results from its Phase 2 clinical trial of RZ402, aimed at treating Diabetic Macular Edema (DME). The study highlighted significant improvements in central subfield thickness (CST), a critical biomarker in DME management, across […]
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU (previously known as EYP-1901). This trial evaluated DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR), revealing that while the treatment exhibits a biologic effect and a favorable safety profile, it […]